Analytical Data
-
基因名
porA
- Application
-
别名
porA；PVS；Poliovirus receptor
-
种属
E.coli
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P0DH58
-
表达区间
20-392aa
-
氨基酸序列
DVSLYGEIKAGVEGRNYQLQLTEAQAANGGASGQVKVTKVTKAKSRIRTKISDFGSFIGFKGSEDLGDGLKAVWQLEQDVSVAGGGATQWGNRESFIGLAGEFGTLRAGRVANQFDDASQAIDPWDSNNDVASQLGIFKRHDDMPVSVRYDSPEFSGFSGSVQFVPIQNSKSAYTPAYYTKNTNNNLTLVPAVVGKPGSDVYYAGLNYKNGGFAGNYAFKYARHANVGRNAFELFLIGSGSDQAKGTDPLKNHQVHRLTGGYEEGGLNLALAAQLDLSENGDKTKNSTTEIAATASYRFGNAVPRISYAHGFDFIERGKKGENTSYDQIIAGVDYDFSKRTSAIVSGAWLKRNTGIGNYTQINAASVGLRHKF
-
分子量
44.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PorA is a key surface protein found in various pathogenic bacteria, particularly in Neisseria species, where it plays a crucial role in immune evasion and bacterial virulence. The study of PorA recombinant proteins has gained significant interest due to their potential applications in vaccine development and diagnostics. Understanding the structure-function relationship of PorA is critical, as it may provide insights into how these proteins interact with host immune systems. Research has demonstrated that PorA can elicit robust immunogenic responses, making it a candidate for inclusion in multivalent vaccines aimed at combating bacterial infections. Furthermore, the production of PorA as a recombinant protein allows for detailed studies of its properties and interactions, facilitating the development of novel therapeutic strategies. The advancement of recombinant DNA technology has enabled researchers to produce PorA in sufficient quantities, leading to a better understanding of its antigenic characteristics and potential protective efficacy. As antibiotic resistance becomes an escalating concern, the exploration of recombinant PorA in various contexts, such as vaccine formulation and therapeutic intervention, is timely and essential. Thus, ongoing research into PorA recombinant proteins not only enhances our understanding of bacterial pathogenesis but also paves the way for innovative approaches to prevent and treat bacterial infections.
